On Thursday 13 March 2025, IDIBAPS held the first meeting of the new research project ‘AECC-IDIBAPS Excellence Programme: Immunotherapy Against Cancer’. Funded by the Spanish Association Against C...
Read moreLa colaboración del Complejo Asistencial Universitario de Salamanca a través del IBSAL y del Hospital Virgen de Rocío, mediante el Instituto de Biomedicina de Sevilla, ha logrado la financiación d...
Read moreHospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulatory authority (AEMPS).
Read moreThe round recognizes recent FDA alignment to advance NRTX-1001 into the Phase 3 EPIC (EPIlepsy Cell therapy) trial
Read moreLa medicina personalizada o de precisión aprovecha los avances biotecnológicos en diversas disciplinas para mejorar el diagnóstico y adaptar las terapias a la singularidad de cada paciente.
Read moreCulmina el proyecto estratégico de I+D SOCRATHeS, coordinado por el Cima Universidad de Navarra con la financiación del Gobierno de Navarra
Read moreInnovative 6,000-square-foot facility enables clinical and commercial process development support to help cell therapy developers transition from research-scale to commercialization
Read moreIt has been developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma
Read moreLa sanidad pública madrileña ha tratado con éxito por primera vez en el mundo una enfermedad autoinmune muy rara con CAR-T, terapia de modificación genética de determinadas células del sistema i...
Read moreAAVion®, a fully integrated AAV manufacturing platform designed to accelerate gene therapy development. A ready-to-use Plasmid Platform intended to meet the increasing demand for plasmid DNA
Read moreVHIO cordinates the EU-funded PragmaTIL project. funded by the EU. The initiative brings together 12 institutions from 6 countries with the aim of optimizing the treatment of patients with refractory ...
Read moreEl medicamento de terapia avanzada HCR045, que se administra a las pacientes, está basado en las células HC016, células madre del tejido adiposo patentadas por Histocell y con una mayor capacidad d...
Read more